Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Non-targeted serum metabolomic profiling of prostate cancer patients (FI-TWIM-MS PCa )

ABSTRACT: Non-targeted metabolomics study of serum samples from prostate cancer and healthy individuals using flow injection ion mobility mass spectrometry

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Blood

DISEASE(S): Cancer

SUBMITTER: Xiaoling Zang

PROVIDER: ST001042 | MetabolomicsWorkbench | Thu Jun 07 00:00:00 BST 2018

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

The use of Nitric Oxide as a Radiosensitiser of Hypoxic Prostate Cancer Characterized by Data Independent Label-free Ion Mobility LC-MS

Project description:The use of Nitric Oxide as a Radiosensitiser of Hypoxic Prostate Cancer Characterized by Data Independent Label-free Ion Mobility LC-MS

2020-02-27 | PXD009047 | Pride

Targeted LC MS of acylcarnitines: TLCMS

Project description:Acylcarnitines (panel of 66 quantitated acylcarnitines) analyzed by LC/MS/MS using flow injection analysis with electrospray ionization

2015-01-08 | ST000138 | MetabolomicsWorkbench

High Field Asymmetric Waveform Ion Mobility Spectrometry in Non-targeted Bottom-up Proteomics of Dried Blood Spot

Project description:Dried Blood Spots samples are a rich source of proteins and have therefore great potential for proteomics biomarker discovery studies. Only a few articles have used DBS samples for non-targeted bottom-up protein analysis, probably due to the complexity of the DBS samples. Gas-phase separation by ion mobility spectrometry such as Field Asymmetric Waveform Ion Mobility (FAIMS) could be useful in analysis of DBS samples as FAIMS has previously shown to be advantageous for bottom-up protein analysis of complex samples. The aim of this project was therefore to evaluate FAIMS in non-targeted analysis of Dried Blood Spots.

2018-05-03 | PXD007926 | Pride

Serum proteomics in prostate cancer patients vs. healthy and benign prostate hyperplasia

Project description:The study aim was to identify novel serum markers of prostate cancer diagnosis compared to benign prostate hyperplasia and healthy controls

2016-10-04 | PXD004575 | Pride

Urinary exosomal small non-coding RNA expression of prostate cancer patients

Project description:Small non-coding RNA profiling of urine exosomal total RNA from patients with or without prostate cancer were performed using Affymetrix GeneChip miRNA 4.0 to identify small non-coding RNA profile that can be used for prostate cancer diagnosis.

2020-07-29 | GSE138740 | GEO

Urinary exosomal small non-coding RNA expression of prostate cancer patients

Project description:Small non-coding RNA profiling of urine exosomal total RNA from patients with or without prostate cancer were performed using Affymetrix miRNA Gene-Chip 4.0 to identify small non-coding RNA proflie that can be used for prostate cancer diagnosis.

2020-10-08 | GSE159177 | GEO

Improved sensitivity of ultra-low flow LC-MS-based proteomic profiling of limited samples using monolithic capillary columns and FAIMS technology

Project description:In this work, we pioneered a combination of ultra-low flow (ULF) high-efficiency ultra-narrow bore monolithic LC columns coupled to MS via a high-field asymmetric waveform ion mobility spectrometry (FAIMS) interface to evaluate the potential applicability for high sensitivity, robust and reproducible proteomic profiling of low ng-level complex biological samples.

2021-01-10 | PXD020669 | Pride

Prostate cancer progression: From non-malignant to bone metastasisProstate cancer progression: From non-malignant to bone metastasis

Project description:Proteome characterization of gland confined prostate tumors and non-malignant prostate tissue. Whole cell protein extracts were purified from FFPE radical prostatectomy specimens for a total of 28 tumor samples and 8 adjacent non-malignant prostate tissues. Associated ProteomeXchange identifiers: PXD003430, PXD003452, PXD003515, PXD004132, PXD003615, PXD003636. Quantitative proteomic analysis of adjacent non-malignant prostate tissue (n=8) and gland confined prostate tumors (n=28) obtained from radical prostatectomy procedures; and bone metastatic prostate tumors (n=22) obtained from patients operated to relief spinal cord compression. At the time of surgery, most metastatic patients had relapsed after androgen-deprivation therapy, while 5 were previously untreated.

2018-08-21 | PXD009868 | Pride

Characterisation of HMGB1 interactome in PNT2 prostate cells

Project description:HMGB1 and HMGB2 are members of the High Mobility Group (HMG) protein superfamily that contain a DNA binding domain (HMG-Box), and their overexpression has been related to main cancer hallmarks, tumor progression, metastasis formation and bad prognosis. We have used yeast two hybrid and affinity purification-mass spectrometry to explore HMGB1 and HMGB2 protein interactions in prostate and ovarian epithelial cells.

2018-05-07 | PXD007867 | Pride

Non-invasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation

Project description:Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with phenotypic subtypes that drive differences in therapy response and outcomes. Histologic transformation to castration-resistant neuroendocrine prostate cancer (CRPC-NE) is associated with distinct epigenetic alterations, including acquired changes in DNA methylation. The current diagnosis of CRPC-NE is challenging and relies on metastatic biopsy. Here, we developed a targeted DNA methylation assay based on the analysis of large tissue datasets to detect CRPC-NE using plasma cell-free DNA (cfDNA) non-invasively. The assay quantifies tumor content and a phenotype evidence score that captures the spectrum of CRPC phenotypes, leveraging a few hundred informative genomic regions to also inform the expression and/or transcriptional state of genes of interest. We qualified the assay in independent clinical cohorts, including 158 plasma samples, achieving a phenotypic evidence score AUC > 0.93 for detecting pathology-confirmed CRPC-NE, and revealing associations between methylation-defined tumor content and clinical outcomes in two prospective phase 2 clinical trials (NCT01799278 and NCT00514540) designed toward aggressive variant CRPC and CRPC-NE, supporting the application of targeted DNA methylation for CRPC-NE detection and patient stratification.

2023-12-11 | GSE245745 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data